Conjugate Vaccines Market Overview Conjugate vaccines are vaccines containing two antigens, one strong and one weak. The stronger antigen is generally made from proteins and is attached to a weaker polysaccharide antigen to form conjugate vaccines. Conjugate vaccines are used to counter diseases whose associated pathogens do not elicit a significant response from the human immune system on their own. As a result, a stronger antigen is attached to the weaker pathogen to make it more prominent and to elicit a stronger response from the immune system. The first conjugate vaccine was developed in response to the outbreak of meningitis, which still remains among the top targeted diseases in the conjugate vaccines market. The global conjugate vaccines market is expected to exhibit a robust 10.5% CAGR over the forecast period, according to MRFR. The growing government support for mass-scale vaccinations for disease eradication is likely to remain the prime driver for the global conjug...